In this issue, the main article will focused on how HTA units in the Asian-Pacific region communicate with their stakeholders in order to push forward their research result. Secondly, we recently greet our two new members, HealthPact (Australia) and Department of Health (the Philippines), therefo

COVID-19 has been inevitably staying with us for almost a year and a half since the first outbreak. It induces us to seek for more knowledge in order to survive and control this harsh situation, not only from healthcare perspective but also economic and political ones. HTA is a great helping hand fo

For full text, click here http://www.translational-medicine.com/content/pdf/1479-5876-11-1.pdf

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha

Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac